Stock Price
0.52
Daily Change
-3.70%
Yearly
-26.75%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,037.00 14.00 0.46% -22.11%
Brainstorm Cell Therapeutics 3.33 -0.15 -4.31% -42.29%
Bioline Rx 2.22 -0.10 -4.31% -4.31%
Celldex Therapeutics 35.68 -1.93 -5.13% 81.95%
Curis 4.49 -0.28 -5.87% 138.83%
CytrRx Corporation 0.52 -0.02 -3.70% -26.75%
Glaxosmithkline 41.25 -0.22 -0.53% 10.00%
J&J 159.38 2.29 1.46% 6.06%
Karyopharm Therapeutics 6.72 -0.56 -7.69% -58.75%
Novartis 80.00 0.05 0.06% -12.68%
Northwest Biotherapeutics 0.80 0.01 1.27% -45.95%
Roche Holding 362.25 -1.20 -0.33% 19.85%
Seattle Genetics 150.74 -7.93 -5.00% -15.90%

Indexes Price Day Year
US2000 2159 -47.02 -2.13% 14.10%
NASDAQ 15085 -295.85 -1.92% 21.03%

CytrRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology and rare diseases. The Company is focused on the discovery, research and clinical development of anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The Company's Linker Activated Drug Release (LADR) technology platform is a discovery engine to create a pipeline of anti-cancer molecules that avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Its product candidate, Aldoxorubicin is a rationally engineered cytotoxic which delivers anti-cancer agent, doxorubicin, into the tumor is in late-stage clinical trials. Its other product candidate, Arimoclomol is also in clinical trials for Niemann Pick disease Type C (NPC) and Gaucher disease through Orphazyme A/S.